



GASTROINTESTINAL CANCERS

Advances in Early-Stage Colorectal Cancer: Integrating Emerging Evidence into Practice

Presented by: Jeffrey Meyerhardt, MD, MPH, *Dana-Farber Cancer Institute*

Overview: Recent clinical trial data has changed the treatment paradigm for early-stage colorectal cancer, particularly for cancers that are dMMR or MSI-H. This session provides education on these new results, and how to best incorporate them into clinical practice, which provides the best quality of treatment to patients.

Learning Objectives:

- Describe current recommendations and best practices for treatment of early-stage colorectal cancer.
- Discuss the results of recent clinical trials for early-stage colorectal cancer and identify how these practice-changing results may be applied to clinical practice.

The Evolving Treatment Landscape for Gastric/Esophageal/EGJ Cancers

Presented by: Mary F. Mulcahy, MD, *Robert H. Lurie Comprehensive Cancer Center of Northwestern University*

Overview: The treatment landscape for gastroesophageal tumors continues to evolve to include a variety of biomarker-based regimens. This session provides the knowledge, competence, and practice skills necessary to optimize care of patients with gastric, esophageal, or esophagogastric junction (EGJ) gastric cancers.

Learning Objectives:

- Evaluate the available evidence, guideline recommendations, and ongoing clinical trial data for targeted therapies and immunotherapies for the treatment of gastric, EGJ, and esophageal cancers.
- Apply current biomarker testing recommendations to guide clinical decision-making and identify patients with gastric, EGJ, or esophageal cancer who will benefit from targeted therapies or immunotherapies.

Novel Treatment Strategies for Management of Advanced Hepatocellular Carcinoma

Presented by: Adam M. Burgoyne, MD, PhD, *UC San Diego Moores Cancer Center*

Overview: HCC is associated with poor prognosis, and many patients are diagnosed at an advanced stage. The treatment landscape has evolved, and multiple new immunotherapies were added to the NCCN Guidelines® for Hepatocellular Carcinoma in recent years. This session outlines new data and updated recommendations, which can be incorporated into treatment strategies to improve patient outcomes.

Learning Objectives:

- Evaluate the data for the different immunotherapy options that are recommended for the first-line treatment of advanced hepatocellular carcinoma.
- Describe the systemic therapy options that are recommended for the subsequent-line treatment of advanced progressive hepatocellular carcinoma.

Appendiceal Cancer Care: What Clinicians Need to Know

Presented by: Stacey A. Cohen, MD, *Fred Hutchinson Cancer Center*

Overview: Appendiceal neoplasms and cancers are rare gastrointestinal tumors that are becoming more common, especially in patients under 50 years of age. This session highlights this rare topic with risk-stratification, treatment, and surveillance protocols.

Learning Objectives:

- Describe current recommendations and best practices for treatment of appendiceal neoplasms and cancers.
- Detail the results from key trials and observational studies on appendiceal neoplasms and cancers and how these results may impact clinical practice.